Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
ALLO — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

15.06

Margin Of Safety %

Put/Call OI Ratio

0.16

EPS Next Q Diff

0.01

EPS Last/This Y

0.15

EPS This/Next Y

-0.03

Price

2.71

Target Price

7.36

Analyst Recom

1.54

Performance Q

91.49

Upside

-518.9%

Beta

0.59

Ticker: ALLO




21 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09ALLO2.510.170.0111759
2026-03-10ALLO2.70.171.4011977
2026-03-11ALLO2.620.190.0212331
2026-03-12ALLO2.470.190.4512363
2026-03-13ALLO2.470.190.4512363
2026-03-17ALLO2.280.180.0215427
2026-03-18ALLO2.150.170.1816501
2026-03-19ALLO2.220.170.2917657
2026-03-20ALLO2.080.170.2317970
2026-03-23ALLO2.430.180.1310109
2026-03-24ALLO2.210.170.7111034
2026-03-25ALLO2.330.170.2011221
2026-03-26ALLO2.420.170.0711297
2026-03-27ALLO2.270.160.0312193
2026-03-30ALLO2.210.160.3112313
2026-03-31ALLO2.430.160.0212476
2026-04-01ALLO2.560.160.0112667
2026-04-02ALLO2.480.160.0612961
2026-04-06ALLO2.610.160.1413089
2026-04-07ALLO2.630.160.3113462
2026-04-08ALLO2.710.160.0113492
DateSymbolLatestP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09ALLO2.5021.7- -0.94
2026-03-10ALLO2.7121.7- -0.94
2026-03-11ALLO2.6321.7- -0.94
2026-03-12ALLO2.4721.7- -0.94
2026-03-13ALLO2.4021.7- -0.94
2026-03-17ALLO2.2721.7- -0.81
2026-03-18ALLO2.1521.7- -0.75
2026-03-19ALLO2.2321.7- -0.75
2026-03-20ALLO2.0735.7- -0.71
2026-03-23ALLO2.4335.7- -0.71
2026-03-24ALLO2.2135.7- -0.74
2026-03-25ALLO2.3335.7- -0.74
2026-03-26ALLO2.4235.7- -0.74
2026-03-27ALLO2.2735.7- -0.74
2026-03-30ALLO2.2135.7- -0.74
2026-03-31ALLO2.4435.7- -0.74
2026-04-01ALLO2.5635.7- -0.74
2026-04-02ALLO2.4835.7- -0.74
2026-04-06ALLO2.6135.7- -0.74
2026-04-07ALLO2.6235.7- -0.74
2026-04-08ALLO2.7135.7- -0.72
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09ALLO-0.352.4013.35
2026-03-10ALLO-0.352.4013.35
2026-03-11ALLO-0.352.4016.00
2026-03-12ALLO-0.352.4016.00
2026-03-13ALLO-0.352.4016.00
2026-03-17ALLO-0.322.2514.75
2026-03-18ALLO-0.382.2514.75
2026-03-19ALLO-0.382.2514.75
2026-03-20ALLO-0.382.2514.75
2026-03-23ALLO-0.381.3414.75
2026-03-24ALLO-0.381.3414.75
2026-03-25ALLO-0.381.3415.06
2026-03-26ALLO-0.381.3415.06
2026-03-27ALLO-0.381.3415.06
2026-03-30ALLO-0.381.3415.06
2026-03-31ALLO-0.381.3415.06
2026-04-01ALLO-0.381.3415.06
2026-04-02ALLO-0.391.3415.06
2026-04-06ALLO-0.391.3415.06
2026-04-07ALLO-0.391.3415.06
2026-04-08ALLO-0.391.3415.06
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.17

Avg. EPS Est. Current Quarter

-0.18

Avg. EPS Est. Next Quarter

-0.16

Insider Transactions

-0.39

Institutional Transactions

1.34

Beta

0.59

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

9

Growth Score

22

Sentiment Score

98

Actual DrawDown %

92.5

Max Drawdown 5-Year %

-97.3

Target Price

7.36

P/E

Forward P/E

PEG

P/S

P/B

2.12

P/Free Cash Flow

EPS

-0.87

Average EPS Est. Cur. Y​

-0.72

EPS Next Y. (Est.)

-0.75

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.6

Return on Equity vs Sector %

-92.5

Return on Equity vs Industry %

-76.1

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.17

EBIT Estimation

ALLO Healthcare
$2.70
📉
Swing / Pullback
Buy the dip on strong trends
39 /100
WEAK
Trend
8/20
Pullback
6/25
Volume
9/15
Valuation
8/20
TP/AR
1/10
Options
7/10
RSI
60.4
Range 1M
80.9%
Sup Dist
6.7%
🚀
Momentum Growth
Ride accelerating trends
N/A
40 /100
WEAK
Momentum
9/25
Growth
14/30
Estimates
0/20
Inst/Vol
7/15
Options
10/10
EPS Yr
7.8%
EPS NY
1.5%
52W%
91%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +172.6% upside
Quality
2/30
Valuation
16/30
Growth
9/25
Stability
6/10
LT Trend
3/5
Upside
+172.6%
Quality
9
Allogene Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 150
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
ALLO

Latest News

Caricamento notizie per ALLO
stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today
news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance
stock history ALLO – Allogene Therapeutics, Inc. invest stock market
stock prices ALLO premarket after hours
ticker ALLO fair value insiders trading